Trends in CTGF Expression in Renal and Chorioretinal Tissues Following Metformin and SGLT2 Inhibitor Treatment in Diabetic Rats
Abstract
BACKGROUND: Connective tissue growth factor (CTGF) plays a central role in fibrotic processes affecting both renal and retinal tissues in diabetes. Although sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to exert renoprotective and antifibrotic effects, their impact on CTGF expression in renal and retinal tissues has not been clearly established. This preliminary study was conducted to evaluate whether SGLT2 inhibitors (SGLT2i) could influence CTGF expression in the kidneys and eyes of diabetes-induced rats.
METHODS: After two weeks of adaptation, 24 rats were randomized and distributed equally into four groups (n=6 each): 1) Healthy Control, healthy rats without diabetic induction; 2) Negative Control, diabetic rats induced with streptozotocin (STZ) without treatment; 3) Metformin Group, diabetic rats treated with metformin; and 4) SGLT2i Group, diabetic rats treated with empagliflozin. Following eight weeks of intervention, CTGF expression was analyzed by Western blot in renal tissue (right kidney) and chorioretinal tissue (right eye). Four samples per group yielded analyzable bands and were included in the final quantification.
RESULTS: In renal tissue, CTGF levels (mean±SD) were highest in Negative Control Group (0.81±0.06). Both the Metformin Group (0.58±0.14) and SGLT2i Group (0.57±0.33) demonstrated a trend toward reduced CTGF expression. In chorioretinal tissue, CTGF values were relatively similar across groups (Healthy Control: 0.67±0.05; Negative Control: 0.63±0.12), with Metformin Group (0.61±0.12) and SGLT2i Group (0.64±0.22) showing a modest reduction trend.
CONCLUSION: In diabetic rats, CTGF expression levels are markedly increased. Following treatment with metformin and SGLT2i, CTGF expression demonstrates a noticeable reduction trend.
KEYWORDS: SGLT2 inhibitor, metformin, connective tissue growth factor, cellular communication network factor 2, renal, retina
Full Text:
PDFReferences
Schwarz P. IDF global clinical practice recommendations for managing type 2 diabetes - 2025. Diabetes Res Clin Pract. 2025; 222 (Suppl 1): 112158, CrossRef.
Bermejo S, González E, López-Revuelta K, Ibernon M, López D, Martín-Gómez A, et al. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes. Clin Kidney J. 2023; 16(10): 1656-63, CrossRef.
Wang N, Zhang C. Oxidative stress: A culprit in the progression of diabetic kidney disease. Antioxidants. 2024; 13(4): 455, CrossRef.
Wei L, Sun X, Fan C, Li R, Zhou S, Yu H. The pathophysiological mechanisms underlying diabetic retinopathy. Front Cell Dev Biol. 2022; 10: 963615, CrossRef.
Sambara Y, Arif M, Bahrun U. Pathomechanism of renal damage in type 2 diabetes mellitus patients. Indones Biomed J. 2013; 5(3): 161-8, CrossRef.
Elfiani E, Puspasari A, Arif CW, Maharani C, Ali Z, Suhaimi N, et al. Angiotensin-converting enzyme genetic polymorphism rs4343 as risk of diabetic nephropathy in Jambi-Malay population. Mol Cell Biomed Sci. 2024; 8(1): 37-43, CrossRef.
Kirtaniya AAIK, Lestarini A, Permatananda PANK, Aryastuti AASA. Association of ELMO1 genetic polymorphism (rs741301) with the progression of diabetic kidney disease in Balinese patients with type 2 diabetes mellitus. Mol Cell Biomed Sci. 2023; 7(1): 47-51, CrossRef.
Ren M, Yao S, Chen T, Luo H, Tao X, Jiang H, et al. Connective tissue growth factor: Regulation, diseases, and drug discovery. Int J Mol Sci. 2024; 25(9): 4692, CrossRef.
Fadhillah MR, Arozal W, Wibowo H, Bustami A, Primadhani SW, Khatimah NG, et al. The role of Centella asiatica and its main bioactive compound, asiatic acid in cardiac remodeling: A systematic review of animal studies. Mol Cell Biomed Sci. 2025; 9(1): 1-12, CrossRef.
Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res. 2015; 47(9): 686-92, CrossRef.
Ji K, Zeng X, Wei J, Zhang L, Hao L, Fan M, et al. The SGLT2 inhibitors empagliflozin alleviate renal fibrosis by inhibiting CTGF-mediated epithelial-mesenchymal transition in diabetic sprague-dawley (SD) rats. Preprints. 2024; 2024: 021288, CrossRef.
Abbas NAT, El Salem A, Awad MM. Empagliflozin, SGLT(2) inhibitor, attenuates renal fibrosis in rats exposed to unilateral ureteric obstruction: Potential role of klotho expression. Naunyn Schmiedebergs Arch Pharmacol. 2018; 391(12): 1347-60, CrossRef.
Huang Y, Qian C, Zhou J, Xue J. Investigation of expression and influence of CTGF and HO-1 in rats with diabetic retinopathy. Exp Ther Med. 2020; 19(3): 2291-5, CrossRef.
Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016; 6: 26428, CrossRef.
Zaini LM, Kartasasmita AS, Gondhowiardjo TD, Syukri M, Lesmana R. Expression of GLUT-1 and SGLT-2 in the chorioretina of streptozotocin-induced diabetic rats after administration of empagliflozin. J Ophthalmic Vis Res. 2025; 20: 10.18502/jovr.v20.15231, CrossRef.
Ridwan M, Dimiati H, Syukri M, Lesmana R, Zaini LM. Effects of SGLT2-inhibitor on the expression of microRNA-21, transforming growth factor-β1, and matrix metalloproteinase-2 in the process of cardiac fibrosis in hyperglycemic model rats. Indones Biomed J. 2024; 16(1): 48-55, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Lifestyle modifications and nutraceutical interventions in the prevention and management of metabolic syndrome. Indones Biomed J. 2025; 17(3): 207-32, CrossRef.
Zhang S, Xu H, Yu X, Wu Y, Sui D. Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med. 2017; 14(1): 383-90, CrossRef.
Lu J, Shi J, Li M, Gui B, Fu R, Yao G, et al. Activation of AMPK by metformin inhibits TGF-β-induced collagen production in mouse renal fibroblasts. Life Sci. 2015; 127: 59-65, CrossRef.
Corremans R, Neven E, Maudsley S, Leysen H, De Broe ME, D'Haese PC, et al. Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats. Kidney Int. 2022; 101(5): 929-44, CrossRef.
Huang J, Liu Y, Shi M, Zhang X, Zhong Y, Guo S, et al. Empagliflozin attenuating renal interstitial fibrosis in diabetic kidney disease by inhibiting lymphangiogenesis and lymphatic endothelial-to-mesenchymal transition via the VEGF-C/VEGFR3 pathway. Biomed Pharmacother. 2024; 180: 117589, CrossRef.
Van Geest RJ, Leeuwis JW, Dendooven A, Pfister F, Bosch K, Hoeben KA, et al. Connective tissue growth factor is involved in structural retinal vascular changes in long-term experimental diabetes. J Histochem Cytochem. 2014; 62(2): 109-18, CrossRef.
Roy S, Amin S, Roy S. Retinal fibrosis in diabetic retinopathy. Exp Eye Res. 2016; 142: 71-5, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i6.3886
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
